Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
ALPN

Alpine Immune Sciences

$5.58

(0.00%)

, ADAP

Adaptimmune

$3.81

0.04 (1.06%)

09:58
05/15/19
05/15
09:58
05/15/19
09:58
Recommendations
Alpine Immune Sciences, Adaptimmune analyst commentary at Piper Jaffray »

Piper sees broad…

ALPN

Alpine Immune Sciences

$5.58

(0.00%)

ADAP

Adaptimmune

$3.81

0.04 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

ADAP

Adaptimmune

$3.77

-0.14 (-3.58%)

, ALPN

Alpine Immune Sciences

$5.58

-0.07 (-1.24%)

08:23
05/15/19
05/15
08:23
05/15/19
08:23
Hot Stocks
Adaptimmune announces license agreement with Alpine Immune Sciences »

Adaptimmune (ADAP) and…

ADAP

Adaptimmune

$3.77

-0.14 (-3.58%)

ALPN

Alpine Immune Sciences

$5.58

-0.07 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

Over a week ago
ALPN

Alpine Immune Sciences

$6.38

0.16 (2.57%)

07:29
05/09/19
05/09
07:29
05/09/19
07:29
Hot Stocks
Alpine Immune Sciences expects cash to fund operations into 2021 »

Alpine expects to have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALPN

Alpine Immune Sciences

$6.38

0.16 (2.57%)

07:29
05/09/19
05/09
07:29
05/09/19
07:29
Earnings
Alpine Immune Sciences reports Q1 EPS (70c), consensus (69c) »

"The first quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADAP

Adaptimmune

$4.46

0.26 (6.19%)

15:43
05/07/19
05/07
15:43
05/07/19
15:43
Recommendations
Adaptimmune analyst commentary at Raymond James »

Adaptimmune price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

ADAP

Adaptimmune

$4.37

-0.28 (-6.02%)

06:20
05/07/19
05/07
06:20
05/07/19
06:20
Downgrade
Adaptimmune rating change at SVB Leerink »

Adaptimmune downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

ADAP

Adaptimmune

$4.65

-0.15 (-3.13%)

07:55
05/06/19
05/06
07:55
05/06/19
07:55
Conference/Events
Adaptimmune to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 31

    May

ADAP

Adaptimmune

$4.65

-0.15 (-3.13%)

07:34
05/06/19
05/06
07:34
05/06/19
07:34
Earnings
Adaptimmune reports Q1 EPS (4c), consensus (31c) »

for the three-month…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 31

    May

ADAP

Adaptimmune

$4.65

-0.15 (-3.13%)

07:16
05/06/19
05/06
07:16
05/06/19
07:16
Hot Stocks
Adaptimmune announces clinical progress in ADP-A2M4 study »

Adaptimmune announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 31

    May

ADAP

Adaptimmune

$4.65

-0.15 (-3.13%)

04:55
05/06/19
05/06
04:55
05/06/19
04:55
Conference/Events
Adaptimmune to host business news update conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.